1. New FDA-Approved Therapeutics
Recent regulatory milestones have dramatically expanded targeted therapy and precision imaging choices for prostate cancer patients, significantly improving survival while maintaining quality of life:
1. Darolutamide (Nubeqa®)
Indication: Approved for metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).
Key Trial: ARANOTE Phase 3 trial demonstrated statistically significant and clinically meaningful improvements in radiographic progression-free survival (rPFS) compared to ADT alone.[1]
2. Lutetium-177 Vipivotide Tetraxetan (Pluvicto®)
Indication: PSMA-targeted radioligand therapy for pre-chemotherapy metastatic castration-resistant prostate cancer (mCRPC).
Key Trial: Expanded approval for earlier line use following progression on one androgen receptor pathway inhibitor (ARPI), supported by the landmark Phase III PSMAfore study.[2]
3. Niraparib + Abiraterone Acetate (AKEEGA®)
Indication: First precision dual-action tablet approved for BRCA2/BRCA1-mutated metastatic castration-sensitive prostate cancer.
Clinical Impact: Achieved a 54% reduction in risk of radiographic progression or death versus standard of care.[3]
4. Piflufolastat F18 (Pylarify®)
Indication: Second PSMA-targeted PET imaging drug for men with prostate cancer.
Clinical Utility: Detects small PSMA-positive metastatic and nodal recurrences undetectable by conventional CT/bone scintigraphy, enabling accurate staging and earlier intervention.[4]
2. Emerging Evidence & Landmark Clinical Trials
Recent randomized controlled trials presented at major international oncology symposia have delivered high-grade evidence for treatment intensification, metastasis-directed radiotherapy, and precision margin reduction:
In the Phase 3 PSMAfore trial, lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617) demonstrated decisive clinical superiority in taxane-naïve patients with PSMA-positive mCRPC whose disease progressed following one prior ARPI:
- Study Design: 468 patients randomized to 177Lu-PSMA-617 (7.4 GBq every 6 weeks, up to 6 cycles) vs. an ARPI switch (abiraterone or enzalutamide).
- rPFS Prolongation: Median rPFS reached 9.30 months vs. 5.55 months at primary analysis (HR 0.41; p < 0.0001), and 11.60 months vs. 5.59 months at the 24-month cutoff (HR 0.49).
- Patient-Reported Quality of Life: Significant delays in time to worsening in FACT-P scores (HR 0.61) and Brief Pain Inventory scores (HR 0.72).
- Skeletal Event Protection: Time to first symptomatic skeletal event (SSE) was markedly prolonged (HR 0.41).[5, 6]
The randomized Phase II RADIOSA trial evaluated whether combining short-course androgen deprivation therapy (ADT) with stereotactic body radiotherapy (SBRT) improves clinical disease control in men with oligorecurrent prostate cancer (≤3 metastatic lesions):
- Efficacy Benefit: Combination arm demonstrated a remarkable improvement in median clinical progression-free survival (32.2 months vs. 15.1 months; HR 0.43, p = 0.001).
- Risk Reduction: Represents a 57% reduction in the risk of clinical progression.
- Safety Profile: Outstanding tolerability with minimal Grade ≥3 toxicity and zero treatment-related mortalities.[7]
The multicenter Phase II EXTEND trial investigated MDT addition to ADT across continuous and intermittent hormone therapy cohorts in oligometastatic prostate cancer:
- PFS Prolongation: Combined cohort PFS reached 36 months vs. 17 months (HR 0.45; p < 0.001). In continuous ADT, median PFS expanded from 22 to 47 months.
- Translational Discovery: Durable remissions strongly correlated with systemic T-cell receptor activation, Th1 cytokines, and CD8+ T-cell proliferation.[8]
Evaluated MRI-guided versus CT-guided stereotactic body radiotherapy in localized prostate cancer. At 2-year analysis, MRI guidance with margin reduction delivered durable protection:
- Late GU Toxicity: 27% with MRI-guided SBRT versus 51% with CT guidance (p = 0.004).
- Late GI Toxicity: 1.4% with MRI-guided versus 9.5% with CT guidance (p = 0.025).
- Patient-Reported Outcomes: Significantly lower deterioration in bowel (OR 0.444) and sexual function (OR 0.366).[9]
3. Updated Therapeutic Outcomes & Biomarkers
Abiraterone Acetate Safety Profile (Individual Patient Meta-Analysis)
A comprehensive meta-analysis of 14 randomized Phase 2 and 3 trials (4,296 patients) evaluated the long-term safety of Abiraterone Acetate in mCRPC. Serious adverse events (Grade 3–5) occurred less frequently with abiraterone (64.1%) compared to standard of care (71.8%). Musculoskeletal disorders and back pain were the most common events; importantly, elderly patients demonstrated no excess age-related safety signals.[10]
PSA Dynamics as Strong Prognostic Marker (ARCHES Phase 3)
Subgroup analysis of 1,150 men in the ARCHES trial demonstrated that combining Enzalutamide with ADT significantly prolonged rPFS across both low and high baseline PSA tiers. Patients achieving undetectable PSA (<0.2 ng/mL) achieved an 86% reduction in radiographic progression risk (HR 0.14; p < 0.001) and a 76% reduction in risk of death (HR 0.24).[11]
References & Clinical Citations
- FDA. FDA approves darolutamide for metastatic castration-sensitive prostate cancer. (2025). Available from: FDA Center for Drug Evaluation & Research.
- FDA. FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive mCRPC. (2025).
- Johnson & Johnson. U.S. FDA approves AKEEGA® as the first precision dual-action therapy for BRCA2-mutated mCSPC. (2024).
- FDA. FDA approves second PSMA-targeted PET imaging drug for men with prostate cancer (Pylarify®).
- Fizazi, K., et al. Health-related quality of life, pain, and symptomatic skeletal events with [(177)Lu]Lu-PSMA-617 in patients with progressive mCRPC (PSMAfore): an open-label, randomised, phase 3 trial. Lancet Oncol, 2025; 26(7): 948-959.
- Morris, M.J., et al. (177)Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive mCRPC (PSMAfore): a phase 3 randomized controlled trial. Lancet, 2024; 404(10459): 1227-1239.
- Marvaso, G., et al. ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. Lancet Oncol, 2025; 26(3): 300-311.
- Sherry, A.D., et al. Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial. Eur Urol, 2025; 88(5): 496-509.
- Kishan, A.U., et al. Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial. European Urology, 2025; 87(6): 622-625.
- Shaver, A.L., et al. The Safety of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer: An Individual-Participant Data Meta-Analysis. Cancers, 2025; 17, 2747.
- Azad, A.A., et al. Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial. JAMA Network Open, 2025; 8(5): e258751.